Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism

被引:168
|
作者
Hundemer, Gregory L. [1 ,2 ,3 ]
Curhan, Gary C. [1 ,2 ,3 ,4 ]
Yozamp, Nicholas [2 ,3 ]
Wang, Molin [2 ,3 ,4 ]
Vaidya, Anand [2 ,3 ,5 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Renal Med, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA USA
[3] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA
[4] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Dept Biostat, Boston, MA USA
[5] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Ctr Adrenal Disorders, 75 Francis St, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
ARTERIAL-HYPERTENSION; HYPERALDOSTERONISM; EPLERENONE;
D O I
10.1001/jamacardio.2018.2003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Primary aldosteronism (PA) is an ideal condition to evaluate the role of the mineralocorticoid receptor (MR) in the pathogenesis of atrial fibrillation (AF). OBJECTIVE To investigate whether MR antagonist therapy or surgical adrenalectomy in PA influence the risk for incident AF. DESIGN This cohort study included patients aged 18 years and older. Patients with PA and age-matched patients with essential hypertension were identified via electronic health records. Patients with a history of AF, myocardial infarction, congestive heart failure, or stroke were excluded. Data were collected between 1991 and the end of 2016 in an academic medical center, with a mean follow-up duration of approximately 8 years. EXPOSURES Patients with PA treated with MR antagonists or surgical adrenalectomy were compared with patients with essential hypertension. Patients with PA who were treated with MR antagonists were categorized by whether their plasma renin activity remained suppressed (< 1 ng/mL/h) or substantially increased (>= 1 ng/mL/h), as proxies for insufficient or sufficient MR blockade. MAIN OUTCOMES AND MEASURE Incident AF. RESULTS A total of 195 patients with PA who were treated with MR antagonists and 201 patients with PA treated with surgical adrenalectomy were included, as well as 40 092 age-matched patients with essential hypertension. Despite similar blood pressure at study entry and throughout follow-up, patients with PA who were treated with MR antagonists whose renin remained suppressed had a higher risk for incident AF than patients with essential hypertension (adjusted HR, 2.55 [95% CI, 1.75-3.71]). They also had an adjusted 10-year cumulative AF incidence difference of 14.1(95% CI, 6.7-21.5) excess cases per 100 persons compared with patients with essential hypertension. In contrast, patients with PA who were treated with MR antagonists and whose renin increased and patients with PA who were treated with surgical adrenalectomy had no statistically significant difference in risk for incident AF compared with patients with essential hypertension. CONCLUSIONS AND RELEVANCE When compared with patients with essential hypertension, patients with PA treated with MR antagonists such that renin remained suppressed (as a proxy for insufficient MR blockade) had a significantly higher risk for incident AF; however, treatment of PA with MR antagonists to substantially increase renin (suggesting sufficient MR blockade), or with surgical adrenalectomy (to remove the source of aldosteronism), was associated with no significant difference in risk for developing AF. These findings add to the growing body of evidence suggesting that MR blockade may be a potential therapy to decrease the incidence of AF.
引用
收藏
页码:768 / 774
页数:7
相关论文
共 50 条
  • [41] PREDICTORS AND EFFECTS OF COMORBID ATRIAL FIBRILLATION IN HYPERTENSIVE PATIENTS DUE TO PRIMARY ALDOSTERONISM
    Sakaguchi, Shintaro
    Okamoto, Ryuji
    Inoue, Chisa
    Akao, Masaharu
    Kamemura, Kohei
    Takeda, Yoshiyu
    Ohno, Youichi
    Inagaki, Nobuya
    Rakugi, Hiromi
    Tanabe, Akiyo
    Tamura, Kouichi
    Fujita, Satoshi
    Yano, Yutaka
    Dohi, Kaoru
    Naruse, Mitsuhide
    JOURNAL OF HYPERTENSION, 2023, 41 : E291 - E291
  • [42] Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term
    Rossi, Gian Paolo
    Maiolino, Giuseppe
    Flego, Alberto
    Belfiore, Anna
    Bernini, Giampaolo
    Fabris, Bruno
    Ferri, Claudio
    Giacchetti, Gilberta
    Letizia, Claudio
    Maccario, Mauro
    Mallamaci, Francesca
    Muiesan, Maria Lorenza
    Mannelli, Massimo
    Negro, Aurelio
    Palumbo, Gaetana
    Parenti, Gabriele
    Rossi, Ermanno
    Mantero, Franco
    HYPERTENSION, 2018, 71 (04) : 585 - 591
  • [43] Atrial fibrillation And primary aldosteronism: results of the papphy study
    Seccia, Teresa M.
    Letizia, Claudio
    Muiesan, Maria Lorenza
    Lerco, Silvia
    Bisogni, Valeria
    Maiolino, Giuseppe
    Cesari, Maurizio
    Rossi, Gian Paolo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0J) : J33 - J34
  • [44] Prevalence and determinants of non-rheumatic atrial fibrillation in patients with primary aldosteronism
    Mourad, JJ
    Milliez, P
    Massien, C
    Fofol, I
    Safar, M
    Plouin, PF
    Girerd, X
    JOURNAL OF HYPERTENSION, 1998, 16 : S123 - S123
  • [45] Increased Expression of Mineralocorticoid Receptor in Human Atrial Fibrillation and a Cellular Model of Atrial Fibrillation
    Tsai, Chia-Ti
    Chiang, Fu-Tien
    Tseng, Chuen-Den
    Hwang, Juey-Jen
    Kuo, Kuan-Ting
    Wu, Cho-Kai
    Yu, Chih-Chieh
    Wang, Yi-Chih
    Lai, Ling-Ping
    Lin, Jiunn-Lee
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (08) : 758 - 770
  • [46] Incidence and progression of atrial fibrillation in patients with and without heart failure using mineralocorticoid receptor antagonists: a meta-analysis
    Rodrigues, Thalys Sampaio
    Quarto, Levindo Jose Garcia
    Nogueira, Savio Carvalho
    Koshy, Anoop N.
    Mahajan, Rajiv
    Sanders, Prashanthan
    Ekinci, Elif I.
    Burrell, Louise M.
    Farouque, Omar
    Lim, Han S.
    CLINICAL RESEARCH IN CARDIOLOGY, 2024, 113 (06) : 884 - 897
  • [47] Assessment of cardiovascular disease risk by plasma renin activity changes in patients with primary aldosteronism on mineralocorticoid receptor antagonist treatment
    Satoshi Morimoto
    Atsuhiro Ichihara
    Hypertension Research, 2022, 45 : 1517 - 1519
  • [48] The Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation
    Lavall, Daniel
    Selzer, Christian
    Schuster, Pia
    Lenski, Matthias
    Adam, Oliver
    Schaefers, Hans-Joachim
    Boehm, Michael
    Laufs, Ulrich
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (10) : 6656 - 6668
  • [49] Assessment of cardiovascular disease risk by plasma renin activity changes in patients with primary aldosteronism on mineralocorticoid receptor antagonist treatment
    Morimoto, Satoshi
    Ichihara, Atsuhiro
    HYPERTENSION RESEARCH, 2022, 45 (09) : 1517 - 1519
  • [50] OBSTRUCTIVE SLEEP APNOEA IS COMMON IN PATIENTS WITH PRIMARY ALDOSTERONISM AND IMPROVES WITH ADRENALECTOMY OR MINERALOCORTICOID RECEPTOR ANTAGONISTS
    Wolley, M. J.
    Cowley, D.
    Ahmed, A.
    Gordon, R. D.
    Stowasser, M.
    HYPERTENSION, 2016, 67 (05) : E20 - E20